[October 21, 2014]

Research and Markets: Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical

Research and Markets (http://www.researchandmarkets.com/research/gbp6qj/global_potential) has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020" report to their offering.

Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD).

Ebola therapeutics and vaccines market is segmented on the basis of geography into North merica, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease.

Summary

As an example, government of the United States, through the FDA, has granted Fast Track designation to the Tekmira's TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan (News - Alert) Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by providing funds and floating favorable policies.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

• Market Definition and Scope
• Key Findings
• Key market player positioning
• Ebola Virus Key Facts
• Amend for anti-Ebola disease drugs in United States
• Guidance on Air Medical Transport for Patients with Ebola Virus Disease
• Fast Track designation to Anti-E bola drugs research from the U.S. government
• ZMMP Drug: An Orphan solution for E-bola viral disease
• Ethical Dilemmas from therapeutics
• Tekmira Pharma received boost to ebola R&D through FDA fundings
• Clinical Trials
• Market Dynamics

Chapter 4 Forecast Scenario Analysis Of Ebola Vaccines, 2013-2020, ($Million)

• Moderate growth scenario
• Rapid growth scenario
• Diminishing growth scenario

Chapter 5 Global Pipeline And Market Potential Analysis Of E-Bola Therapeutic Vaccines Market By Geography, 2013 - 2020

Chapter 6 Company Profiles

• Tekmira Pharmaceuticals
• BioCryst Pharmaceutical Inc.
• Serepata Therapeutics
• NewLink Genetics Corp.
• Mapp Biopharmaceutical

For more information visit http://www.researchandmarkets.com/research/gbp6qj/global_potential

[ Back To TMCnet.com's Homepage ]